Navigation Links
Newer antimalarials more effective than quinine against severe malaria
Date:3/15/2011

Quinine should no longer be the drug of choice for treating severe malaria, according to an updated systematic review by Cochrane researchers. It is now evident that the antimalarial drug artesunate, which is derived from herbs used in Chinese medicine, is more effective at preventing death in patients with severe malaria.

Severe malaria occurs when the disease affects the function of vital organs. It is associated with rarer cerebral malaria, which affects the brain and can lead to long-term disability. More than a million people die each year from severe malaria, the majority in Sub-Saharan Africa. Artesunate was recommended as the preferred treatment for adults with severe malaria by the World Health Organization (WHO) in 2006, but there was insufficient evidence at the time to recommend a change from the standard treatment of quinine in children.

The researchers updated the review of artesunate by adding a new large multicentre trial of African children published in the Lancet in 2010 to the existing 8 trials. The review now includes a total of 1664 adults and 5765 children, from a variety of settings across Africa and Asia. According to the results, taking artesunate reduces the risk of death by 39% in adults and 24% in children compared to quinine. In adults, deaths caused by severe malaria were reduced from 241 per 1000 with quinine to 147 with artesunate. In children, deaths were reduced from 108 per 1000 with quinine to 83 with artesunate.

"There is now enough evidence to be confident of these results in adults and children," said Peter Olumese of the WHO's Global Malaria Programme. "Intravenous artesunate is now being recommended as the treatment of choice for adults and children with severe malaria anywhere in the world."

Although more children given artesunate suffered neurological problems compared to those given quinine, these were largely resolved within a month of treatment, and were outweighed by the increase in survival rates. "The balance of benefits and harms is in favour of treatment with artesunate," said David Sinclair of the Liverpool School of Tropical Medicine in Liverpool, UK, who led the review team.


'/>"/>

Contact: Jennifer Beal
healthnews@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Research shows rapid adoption of newer, more expensive prostate cancer treatments
2. Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
3. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
4. Decrease in suicide not linked to newer antidepressants
5. Newer Drugs Beat Gleevec in Head-to-Head Trials
6. In infant heart surgery, newer technique yields better survival in first year of life
7. Newer Genetic Info Adds Little to Predicting Breast Cancer
8. Newer Blood Thinner Beats Plavix for Bypass Patients
9. Newer Genetic Test for Autism More Effective
10. Newer Blood Test Predicts Diabetes, Heart Disease
11. Newer cornea transplant surgery shows short- and long-term promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the ... CEO. , Bright Pink is proud to announce Katie Thiede as their new Chief ... new role as Chairman of the Board and launched a national search to find ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum of ... anyone, anywhere to track their cognitive health, and share results with their physicians. Members ... health on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, ... the company’s VideoMedicine mobile platform has launched Quick Care, a new service offering ... Quick Care provides patients with the option to request and begin a consultation ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced ... in people with addiction who are served by MAP’s patient engagement ecosystem. Lief ... that monitors heart and breath rates to identify anxiety levels and can provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: